New Brunswick, NJNCT06057935Now EnrollingIRB Ready

Peritoneal Mesothelioma Clinical Trial in New Brunswick, NJ

Access cutting-edge peritoneal mesothelioma treatment through this phase 2 clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this New Brunswick location

Preparing your pre-screening questions…

Expert Care in New Brunswick

Access peritoneal mesothelioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related peritoneal mesothelioma treatment provided free

Apply for This New Brunswick Location

Check if you qualify for this peritoneal mesothelioma clinical trial in New Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Brunswick site if eligible
  4. 4Begin participation

About This Peritoneal Mesothelioma Study in New Brunswick

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patient age 18 years or older, both sexes.
Clinical diagnosis of MPM at enrolling institution.
Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution.
Complete or near-complete CRS achieved.
Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
ECOG performance status ≤ 1.
Hematology: ANC ≥ 1,500/µl.
Platelets \> 75,000/µl.
Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min.
Adequate hepatic function: bilirubin \< 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL).
Women of childbearing potential with a negative pregnancy test result (urine or blood) who agree to use an effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
A man participating in this study must agree to utilize a reliable barrier form of contraception for the duration of the study
Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.

Exclusion Criteria

Subjects who have previously undergone intraperitoneal chemotherapy or systemic chemotherapy for peritoneal mesothelioma.
Subjects who have previously received platinum-containing chemotherapy regimens.
Subjects with preoperative or intraoperative biopsy consistent with sarcomatoid mesothelioma, well-differentiated papillary mesothelioma, or benign multicystic mesothelioma.
Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than three years, or indolent tumors for which observation over two years is a reasonable option.
High suspicion for extra-abdominal metastases.
Women who are pregnant or lactating.
Active coronary artery disease (defined as unstable angina or a positive cardiac stress test). Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment or are determined by a cardiologist to be of acceptable perioperative risk.
Uncontrolled hypertension defined as \>140/90 and not cleared for surgery at the time of consent.
New York Heart Association (NYHA) Class II or higher congestive heart failure; restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
History of cerebrovascular disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or place them at an unacceptable risk for participation in the study.
Patients with known cisplatin, carboplatin, pemetrexed or mitomycin allergy.
Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
Any condition that would preclude the ability to deliver appropriate IP therapy.
Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
Life expectancy \< 12 weeks.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Brunswick?

Yes, this clinical trial (NCT06057935) has an active research site in New Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Peritoneal Mesothelioma Treatment Options in New Brunswick, NJ

If you're searching for peritoneal mesothelioma treatment options in New Brunswick, NJ, this clinical trial (NCT06057935) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Brunswick research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced peritoneal mesothelioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all peritoneal mesothelioma clinical trials near you to find additional studies recruiting in your area.

More Mesothelioma Trials in New Brunswick, NJ

See all mesothelioma clinical trials recruiting in New Brunswick — not just this study.

Browse Mesothelioma Trials in New Brunswick →

Browse More Trials by Condition

Mesothelioma TrialsPulmonary Embolism TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Brunswick, NJ